Qurient: Dual Payload ADC 'QP101' Shows Higher Response Rate Than Enhertu
Presentation at AACR D3 2026
QP101 Shows 53.6% Response Rate, Surpassing Enhertu (42.9%)
Potential Applications in Ultra-Low HER2 Expression and Enhertu-Resistant Tumors
Qurient announced on July 23 that it released the results of the preclinical efficacy and non-human primate (NHP) toxicity studies of its HER2-targeting dual payload antibody-drug conjugate (ADC) QP101 at ‘AACR D3 2026’ held in Boston, USA.
Qurient presented the results of mouse experiments based on patient-derived xenograft (PDX) models, which involved implanting tumors from 28 patients with HER2-positive solid tumors. In these HER2-positive solid tumor models, QP101 demonstrated a response rate of 53.6%, which was higher than that of Enhertu at the same dosage (42.9%). In models with ultra-low HER2 expression, the drug’s efficacy at high doses was also confirmed.
In repeated-dose toxicity studies in non-human primates, three intravenous doses of 10, 30, and 90 mg/kg were administered at three-week intervals. Dose-proportional systemic exposure was observed, and even at the highest dose of 90 mg/kg, there were no significant toxic findings in clinical symptoms, body weight, or hematology. The company stated that these results indicate a therapeutic index (TI) greater than 30-fold.
QP101 is a dual payload ADC in which two copies each of a TOP1 inhibitor and a CDK7 inhibitor are conjugated to trastuzumab. The two drugs, with different mechanisms of action, independently exert antitumor effects, while the CDK7 inhibitor is designed to enhance the sensitivity of tumor cells to the TOP1 inhibitor.
Hot Picks Today
Karina Fetches 6.7 Billion Won, Lives Under 24-Hour Armed Guard... World's Most Expensive Cow in the Spotlight
- "If It Breaks, That's It": Chaos Among Samsung and SK hynix Consumers... Soaring SSD Prices Mean "No Replacement, Only Refund at Original Price"
- "I'll Pay with Both Shares and Cash" vs "Cash Only"... Why Chey Taewon Filed a Further Appeal After Careful Deliberation
- Yu In-chon: "Even Sadder Than Last Year"...Bicycle Pilgrimage to Mark Brother's First Anniversary
- Do Night Runners Need Sunscreen? MFDS Says "UV from Streetlights Has Minimal Impact"
Nam Kiyeon, CEO of Qurient, stated, "This announcement demonstrated that QP101 is a dual payload ADC capable of achieving both strategic objectives," adding, "The competitiveness of Qurient’s dual payload strategy has been validated at a conference committed to the most innovative drug development, and we expect this approach to gain further attention moving forward."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
